Regeneron Pharmaceuticals
REGN
1,080 hedge funds and large institutions have $64B invested in Regeneron Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 114 funds opening new positions, 368 increasing their positions, 417 reducing their positions, and 86 closing their positions.
55% more funds holding in top 10
Funds holding in top 10: 22 → 34 (+12)
33% more first-time investments, than exits
New positions opened: 114 | Existing positions closed: 86
16% more capital invested
Capital invested by funds: $55B → $64B (+$9B)
2% more funds holding
Funds holding: 1,064 → 1,080 (+16)
0.52% more ownership
Funds ownership: 86.15% → 86.68% (+0.52%)
12% less repeat investments, than reductions
Existing positions increased: 368 | Existing positions reduced: 417
21% less call options, than puts
Call options by funds: $1.17B | Put options by funds: $1.49B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$399M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$125M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$84.7M |
| 4 |
Janus Henderson Group
London,
|
+$81.7M |
| 5 |
Jane Street
New York
|
+$69.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Harris Associates
Chicago,
Illinois
|
-$248M |
| 2 |
Renaissance Technologies
New York
|
-$236M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$112M |
| 4 |
Two Sigma Advisers
New York
|
-$103M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$75.6M |
REGN Hedge Fund Activity: Q3 2022 in Review
1,080 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2022, worth a combined $64B — up 16% from $55B a quarter earlier.
Buyers outnumbered sellers: 114 funds opened new REGN positions and 86 closed out — a net gain of 28 holders — while 368 added to existing stakes and 417 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $399M. The largest seller was Harris Associates, cutting an estimated $248M.
- 1,080 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2022, up from 1,064 in Q2 2022.
- Funds reported $64B of Regeneron Pharmaceuticals stock for Q3 2022, up 16% quarter-over-quarter.
- 114 funds opened new Regeneron Pharmaceuticals positions in Q3 2022 and 86 closed out, a net change of +28 holders.
- The largest Regeneron Pharmaceuticals buyer in Q3 2022 was Fidelity Investments, an estimated $399M added.
- The largest Regeneron Pharmaceuticals seller in Q3 2022 was Harris Associates, an estimated $248M sold.
Based on aggregated 13F filings for Q3 2022.